Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.55 |
| ▸ | CYSLTR1 | Q9Y271 | 17/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8595801 | 1.00 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1PIM1 | |
| SCHEMBL8595806 | 1.00 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1PIM1 | |
| SCHEMBL8554758 | 0.85 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1 | |
| SCHEMBL8554761 | 0.85 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1 | |
| SCHEMBL8558976 | 0.81 | CYSLTR1 (0.50) | CYSLTR2CYSLTR1 | |
| SCHEMBL8558974 | 0.81 | CYSLTR1 (0.50) | CYSLTR2CYSLTR1 | |
| SCHEMBL8558979 | 0.81 | CYSLTR1 (0.50) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3028013 | 0.80 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3030654 | 0.80 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL8553296 | 0.77 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0840728-A1 | HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1998-05-13 | — | — | EP | disclosed |
| US-5750539-A | ANTIASTHMATICS | MERCK FROSST CANADA (CA) | 1998-05-12 | — | — | US | disclosed |
| WO-1996040638-A1 | HETEROARYL DIOL ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (US) | 1996-12-19 | — | — | WO | disclosed |